Navigation Links
PNNL recognized for transferring innovations to the marketplace
Date:12/20/2012

RICHLAND, Wash. Pacific Northwest National Laboratory has been recognized for creating technologies or processes that can store large amounts of renewable energy until it's needed, fight cancer and detect explosives, and then moving the innovations to the marketplace.

The Federal Laboratory Consortium announced today that the Department of Energy national laboratory in Richland is receiving three 2013 Excellence in Technology Transfer awards. The consortium is a nationwide network that encourages federal laboratories to transfer laboratory-developed technologies to commercial markets. With these awards, PNNL has been honored by the FLC more than any other federal laboratory, collecting 78 awards since the program began in 1984.

The 2013 awards will be presented April 25 at the consortium's annual meeting in Westminster, Colo.

Renewable energy storage batteries

Developing a technology that can smoothly integrate energy from variable and intermittent sources such as wind and solar power onto the electricity grid while maintaining grid stability has proven challenging. But PNNL researchers, with funding from DOE's Office of Electricity, recently made significant progress in improving the performance of "redox flow" batteries, which hold promise for storing large amounts of renewable energy and providing greater stability to the energy grid.

First developed in the 1970s, redox flow batteries have shown promise for renewable energy storage but have been limited in their ability to work well in a wide range of temperatures, their relatively high cost and their limited ability to store energy, otherwise known as energy density. The PNNL-developed system incorporates two novel approaches to overcome the limitations of previous generations of redox flow batteries. The result is a dramatically improved operating range, higher energy density and lower cost for vanadium redox flow batteries.

"Successful commercialization of DOE-sponsored technology development, such as this, is vital for creating the grid of the future, and sustaining U.S. leadership in advanced technology," said Imre Gyuk, energy storage program manager at DOE's Office of Electricity.

License agreements with companies like UniEnergy Technologies LLC in Mukilteo, Wash., are expected to lead to commercial products for utilities, power generators and industry.

Therapeutic delivery agent for treating cancers

PNNL researchers created innovative "radiogel" products that allow medical personnel to deliver higher doses of radiation exactly where needed when fighting cancerous tumors that cannot be surgically removed. The treatment is effective, affordable and minimizes exposure to surrounding healthy tissues and organs.

The PNNL-developed, injectable radiogels allow for the delivery of insoluble yttrium-90 a well-established medical radioisotope with many applications in cancer treatment to a precise location for targeted radiation therapy. The radiogels dissolve and disappear once the yttrium-90 decays.

"This new technology will provide doctors with greater flexibility to safely direct radiation therapy to the interior of tumors, as well as to tumor margins following surgical removal," said Darrell Fisher, who leads PNNL's Isotope Sciences Program. "Commercialization of the new treatment will help make it readily available to patients."

DOE's Office of Science provided funding to support early studies on radiogel material composition. A license agreement with Advanced Medical Isotope Corp. of Kennewick, Wash., has led to further development of radiogel products that will eventually be used to treat cancers of the liver, pancreas, brain, neck, and kidneys.

Next-generation microchip Ion Mobility Spectrometer

Researchers at PNNL and Owlstone Ltd., in Cambridge, England, collaborated over a period of several years to successfully develop new technology with the potential to dramatically improve the ability to detect and identify very small amounts of chemicals, such as those that are telltale signs of hidden explosives or disease-revealing proteins in blood.

The Ion Mobility Spectrometer on a Microchip, or IMS Microchip, overcomes limitations of previous sample analytical instruments by shrinking a key component a channel through which molecules must travel. This advance improves performance by allowing higher electric currents to be effectively utilized in the separations process. The dime-sized chip provides dozens of channels through which ions travel to be separated and identified.

Owlstone scientists provided the microfabrication design and methods lying at the foundation of IMS Microchips, while PNNL provided its capabilities in ion mobility spectrometry and mass spectrometry to improve the detection limits and sensitivity of the next generation of analytical microchips.

The unique expertise and capabilities contributed by PNNL researchers were critical to Owlstone in its efforts to successfully develop a commercial IMS Microchip tailored to meet the needs of the mass spectrometry research community.


'/>"/>

Contact: Greg Koller
greg.koller@pnnl.gov
509-372-4864
DOE/Pacific Northwest National Laboratory
Source:Eurekalert

Related biology news :

1. 60th anniversary of NSF Grad Research Fellowship Program; UM fellow Staatermans video recognized
2. Coral researcher recognized with prestigious award
3. UC Riverside entomologist recognized for research in citrus entomology
4. ONR-funded young innovators recognized by President
5. Micross Components Recognized as Teledyne Electronic Manufacturing Services Manufacturer of the Year
6. Research warns Asia unlikely to achieve climate, poverty goals unless womens rights are recognized
7. Patel recognized with NSF Career Award for computer-modeling research on cell membranes
8. Wake Forest Baptist Medical Center Launches Wake Forest Innovations
9. ESMO 2012 Congress: A path for medical oncology innovations
10. PuraMed BioScience®, Inc., Launches a Marketing Blitz for LipiGesic® M, Its Clinically-Tested Migraine Pain Reliever in the Denver, CO Region to Coincide with the NACDSs Marketplace 2012 Trade Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:4/28/2016)... SAN FRANCISCO and BANGALORE, India ... part of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... service provider, today announced a global partnership that ... convenient way to use mobile banking and payment services. ... Mobility is a key innovation area for financial services, but ...
(Date:4/19/2016)... 20, 2016 The new GEZE ... compact web-based "all-in-one" system solution for all door components. ... or the door interface with integration authorization management system, ... systems. The minimal dimensions of the access control and ... building installations offer considerable freedom of design with regard ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the ... today the Clinical Reach Virtual Patient Encounter CONSULT module which enables both ... physician and clinical trial team. , Using the CONSULT module, patients and physicians can ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... will join the faculty of the University of North Carolina Kenan-Flagler Business ... strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international ...
(Date:6/27/2016)... --  Ginkgo Bioworks , a leading organism design ... awarded as one of the World Economic Forum,s ... innovative companies. Ginkgo Bioworks is engineering biology to ... in the nutrition, health and consumer goods sectors. ... including Fortune 500 companies to design microbes for ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
Breaking Biology Technology: